Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET

Cell Cycle

Volumn 11, Issue 19, 2012, Pages 3536-3542

  Liu, Qian ^a   Leber, Brian ^a   Andrews, David W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

ABT 263; ABT 737; Bcl 2; Bcl XL; BH3 only proteins; Bim; Live MCF 7 cells; Mitochondria; Protein protein interactions

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; BIM PROTEIN; NAVITOCLAX; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID;

APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE LIFETIME IMAGING MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN TISSUE; MICROSCOPY; MITOCHONDRION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION;

EID: 84867266361     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21462     Document Type: Article

References (29)

1. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37:299-310; PMID:20159550; http://dx.doi.org/10.1016/j. molcel.2010.01.025.
2. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59; PMID:18097445; http://dx.doi.org/10.1038/nrm2308.
3. Slavov N, Dawson KA. Correlation signature of the macroscopic states of the gene regulatory network in cancer. Proc Natl Acad Sci U S A 2009; 106:4079-84; PMID:19246374; http://dx.doi.org/10.1073/pnas.0810803106.
4. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-32; PMID:19228717; http://dx.doi.org/10.1158/1078-0432.CCR-08-0144.
5. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81; PMID:15902208; http://dx.doi.org/10.1038/ nature03579.
6. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 2007; 50:641-62; PMID:17256834; http://dx.doi.org/10.1021/jm061152t.
7. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26:2374-80; PMID:17016430; http://dx.doi.org/10.1038/sj. onc.1210028.
8. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68:2321-8; PMID:18381439; http://dx.doi.org/10. 1158/0008-5472.CAN-07-5031.
9. Kang MH, Kang YH, Szymanska B, Wilczynska- Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110:2057-66; PMID:17536015; http://dx.doi.org/10.1182/blood- 2007-03-080325.
10. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68:3421-8; PMID:18451170; http://dx.doi.org/10.1158/0008-5472.CAN-07-5836.
11. Aranovich A, Liu Q, Collins T, Geng F, Dixit S, Leber B, et al. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. Mol Cell 2012; 45:754-63; PMID:22464442; http://dx.doi.org/10.1016/j.molcel.2012.01.030.
12. Wong C, Anderson DJ, Lee EF, Fairlie WD, Ludlam MJ. Direct visualization of Bcl-2 family protein interactions using live cell fluorescent protein redistribution assays. Cell Death Dis 2012; 3:e288; PMID:22460384; http://dx.doi.org/10.1038/cddis.2012.28.
13. Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007; 12:897-911; PMID:17453159; http://dx.doi.org/10.1007/s10495-007-0746-4.
14. Leber B, Lin J, Andrews DW. Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 2010; 29:5221-30; PMID:20639903; http://dx.doi.org/10.1038/onc.2010.283.
15. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 2008; 135:1074-84; PMID:19062087; http://dx.doi.org/10.1016/j.cell.2008.11.010.
16. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17:393-403; PMID:15694340; http://dx.doi.org/10.1016/j.molcel.2004.12.030.
17. Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27(Suppl 1):S128-36; PMID:19641498; http://dx.doi.org/10.1038/onc.2009.50.
18. Annis MG, Soucie EL, Dlugosz PJ, Cruz-Aguado JA, Penn LZ, Leber B, et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005; 24:2096-103; PMID:15920484; http://dx.doi.org/10. 1038/sj.emboj.7600675.
19. Annis MG, Zamzami N, Zhu W, Penn LZ, Kroemer G, Leber B, et al. Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene 2001; 20:1939-52; PMID:11360178; http://dx.doi.org/10.1038/sj.onc.1204288.
20. Billen LP, Kokoski CL, Lovell JF, Leber B, Andrews DW. Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol 2008; 6:e147; PMID:18547146; http://dx.doi.org/10.1371/journal.pbio.0060147.
21. Dlugosz PJ, Billen LP, Annis MG, Zhu W, Zhang Z, Lin J, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J 2006; 25:2287-96; PMID:16642033; http://dx.doi.org/10.1038/sj.emboj.7601126.
22. Kim PK, Annis MG, Dlugosz PJ, Leber B, Andrews DW. During apoptosis bcl-2 changes membrane topology at both the endoplasmic reticulum and mitochondria. Mol Cell 2004; 14:523-9; PMID:15149601; http://dx.doi.org/10.1016/S1097-2765(04) 00263-1.
23. Chen Y, Mills JD, Periasamy A. Protein localization in living cells and tissues using FRET and FLIM. Differentiation 2003; 71:528-41; PMID:14686950; http://dx.doi.org/10.1111/j.1432-0436.2003.07109007.x.
24. Chen Y, Periasamy A. Characterization of two-photon excitation fluorescence lifetime imaging microscopy for protein localization. Microsc Res Tech 2004; 63:72-80; PMID:14677136; http://dx.doi.org/10.1002/jemt.10430.
25. Wallrabe H, Periasamy A. Imaging protein molecules using FRET and FLIM microscopy. Curr Opin Biotechnol 2005; 16:19-27; PMID:15722011; http://dx.doi.org/10.1016/j.copbio.2004.12.002.
26. Zacharias DA, Violin JD, Newton AC, Tsien RY. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science 2002; 296:913-6; PMID:11988576; http://dx.doi.org/10.1126/science.1068539.
27. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996; 10:2859-69; PMID:8918887; http://dx.doi.org/10.1101/gad.10.22.2859.
28. Mergenthaler P, Kahl A, Kamitz A, van Laak V, Stohlmann K, Thomsen S, et al. Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state. Proc Natl Acad Sci U S A 2012; 109:1518-23; PMID:22233811; http://dx.doi.org/10.1073/pnas.1108225109.
29. Rasband WS. ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA. http://imagejnihgov/ij/ 1997-2011.